From NMPA to FDA: Leveraging China Approval for U.S. Market Entry

This episode details the process for medical device manufacturers to obtain FDA 510(k) clearance in the United States after securing Class III approval from China's NMPA. We explain that there is no direct reciprocity and outline how to strategically leverage existing Chinese technical documentation, clinical data, and testing reports. The focus is on conducting a thorough gap analysis to meet the FDA's unique requirements, particularly the concept of "substantial equivalence" to a predicate device and compliance with 21 CFR Part 820 for quality management systems. • Does my NMPA Class III approval guarantee FDA clearance? • How can I use my clinical trial data from China for an FDA submission? • What is a "predicate device" and why is it crucial for a 510(k)? • Do I need to repeat all my device testing for the U.S. market? • What are the key differences between China's GMP and the FDA's Quality System Regulation? • What is a gap analysis and why is it the most critical step? • Is it mandatory to submit my 510(k) electronically? • What is a U.S. Agent and do I need to have one? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.